Vol. 4 No. 3 (2016) | ADMET and DMPK

Vol. 4 No. 3 (2016)

Overviews and recent advances in the development of protein kinase inhibitors, Part I.

Guest editor: Godefridus J. Peter

Published: 30-09-2016

Editorial

ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors

Godefridus J. Peters, Kin Tam

ADMET and DMPK, Vol. 4 No. 3 (2016), 182-185

Published 01-10-2016;

DOI: https://doi.org/10.5599/admet.4.3.348
- PDF

Reviews

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer

Jonathan R. Thompson, Smitha P. Menon, Grace K. Dy

ADMET and DMPK, Vol. 4 No. 3 (2016), 186-211

Published 01-10-2016;

DOI: https://doi.org/10.5599/admet.4.3.337
- PDF
Cardiovascular safety of tyrosine kinase inhibitors: Putting their “QT-phobia” in perspective

Rashmi Shah

ADMET and DMPK, Vol. 4 No. 3 (2016), 212-231

Published 01-10-2016;

DOI: https://doi.org/10.5599/admet.4.3.295
- PDF

Original Scientific Articles

Cross talk of c-Jun N-terminal kinase and p38 map kinase modulate insulin and TNFα-stimulated VCAM-1 expression in rat aorta endothelial cells

Gregory B. Pott, Mark Tsurudome, Jamie Bui, Chelsea Gardner, Marc Lee Goalstone

ADMET and DMPK, Vol. 4 No. 3 (2016), 232-240

Published 01-10-2016;

DOI: https://doi.org/10.5599/admet.4.3.314
- PDF
Dose optimization of ceftriaxone-vancomycin combination using fractional inhibitory concentration kinetics in resistant bacteria

Vishnu Dutt Sharma, Aman Singla, Manu Chaudhary, Mukesh Kumar, Anuj Bhatnagar, Shailesh Kumar, Manish Taneja

ADMET and DMPK, Vol. 4 No. 3 (2016), 241-260

Published 01-10-2016;

DOI: https://doi.org/10.5599/admet.4.3.286
- PDF
Evaluation of P-glycoprotein expression in pain relevant tissues: understanding translation of efflux from preclinical species to human

Renu Singh Dhanikula, Cyrla Hoffert, Rebecca Grant, Denis Projean, Rosemarie Panetta, Dajan O'Donnell, Marie Roumi

ADMET and DMPK, Vol. 4 No. 3 (2016), 261-268

Published 01-10-2016;

DOI: https://doi.org/10.5599/admet.4.3.305
- PDF
Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters

Thirumal Eswara Goud, Srinivas Maddi, Nayakanti Devanna, Thatipamula Rajendra Prasad

ADMET and DMPK, Vol. 4 No. 3 (2016), 269-279

Published 01-10-2016;

DOI: https://doi.org/10.5599/admet.4.3.328
- PDF